

1646
Bot-seq
JFW
LUD 5734 US (10105486)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being transmitted via Regular Mail to the United States Patent & Trademark Office at P.O. Box 1450, Alexandria, VA 22313-1450 on October 11, 2004.

Fani Malikouzakis
(Name of Transmitter)

Fani Malikouzakis
(Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: L. DUMOUTIER et al.

U.S. Serial No.: 09/915,735

Group Art Unit: 1646

Filing Date: July 26, 2001

Examiner: Nirmal BASI

For: NOVEL CLASS II CYTOKINE RECEPTORS AND
USES THEREOF

RESPONSE TO COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Communication dated October 5, 2004 (copy enclosed), Applicants submit the following:

- i) Paper Copy of sequence listing;
- ii) Replacement diskette copy of sequence listing; and
- iii) Statement Pursuant to 37 C.F.R. § 1.823(b).

No fee is believed to be due, however, the Commissioner is hereby authorized to deduct any fees due or credit any overpayment to Deposit Account No. 500624.

Respectfully submitted,

By

Norman Hanson

Reg. No. 30,946

Fulbright & Jaworski, L.L.P.

Attorneys for Applicant

666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)



LUD 5734 US (10105486)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being transmitted via Regular Mail to the United States Patent & Trademark Office at P.O. Box 1450, Alexandria, VA 22313-1450 on October 11, 2004.

Fani Malikouzakis
(Name of Transmitter)

Fani Malikouzakis
(Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: L. DUMOUTIER et al.

U.S. Serial No.: 09/915,735

Group Art Unit: 1646

Filing Date: July 26, 2001

Examiner: Nirmal BASI

For: NOVEL CLASS II CYTOKINE RECEPTORS AND
USES THEREOF

STATEMENT PURSUANT TO 37 CFR 1.823(B)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a computer readable copy of the Sequence Listing included in the application.

I hereby state that I have reviewed the paper copy of the Sequence Listing, as required by 37 C.F.R. § 1.821(c), and have reviewed the computer readable form of the Sequence Listing, as required by 37 C.F.R. § 1.821(e), and that the content of the paper and computer readable copies for the above-referenced patent application are the same as required by 37 C.F.R. § 1.821(f).

Early favorable consideration of the patent application is respectfully solicited.

Respectfully submitted,

By

Norman Hanson


Norman Hanson

Reg. No. 30,946

Fulbright & Jaworski, L.L.P.

Attorneys for Applicant

666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)



SEQUENCE LISTING

<110> Dumoutier, Laure
Renauld, Jean-Christophe

<120> Novel Class II Cytokine Receptors and Uses Thereof

<130> LUD 5734 US (10105486)

<140> US 09/915,735

<141> 2001-07-26

<160> 13

<210> 1

<211> 39

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 1

gtccttgtag tcacctcccc cgagcttgta gaatttctg

39

<210> 2

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 2

gtccttgtag tcacctcccc cagctgagga catacttc

38

<210> 3

<211> 39

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 3

gtccttgtag tcacctcccc cttctgtctc ctccatcca

39

<210> 4

<211> 39

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 4

gtccttgtag tcacctcccc cgacgcaagc atttctcag

39

<210> 5

<211> 40

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 5

actgctagct cacttgctgt catcgctcctt gtagtcacct

40

<210> 6

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 6

ggaggactag ttgccagccc cgatgagga

29

<210> 7

<211> 31

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 7

gtgtggcggc cgcaggcatg ggattgacag c

31

<210> 8

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 8

gccggatcca tgcggccgct gccgctgccg

30

<210> 9

<211> 31

<212> DNA

<213> Artificial sequence

<220>

<223> oligonucleotide primer

<400> 9

atcgctagcc atttagcctt gaactctgat g

31

<210> 10
 <211> 27
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> oligonucleotide primer

 <400> 10
 gtggctagcc tggtatgttt tgcccat 27

<210> 11
 <211> 28
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> oligonucleotide primer

 <400> 11
 gcgaattcgt ctggcaaaca tttattga 28


<210> 12
 <211> 25
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> oligonucleotide primer
 <400> 12
 ttggctagca acaatgttct aggtc 25

<210> 13
 <211> 26
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> oligonucleotide primer

 <400> 13
 tgggcgcggc cgcaaacctg tgagat 26



UNITED STATES PATENT AND TRADEMARK OFFICE




UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/915,735	07/26/2001	Laure Dumoutier	LUD 5734 (10105486)	7869
24972	7590	10/05/2004	EXAMINER	
FULBRIGHT & JAWORSKI, LLP 666 FIFTH AVE NEW YORK, NY 10103-3198			BASI, NIRMAL SINGH	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 10/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

09/915735

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT

PAPER

20040929

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed 3/28/04 is not fully responsive to the Office communication mailed 1/2/03 for the reason(s) set forth below or on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report.


Since the above-mentioned reply appears to be bona fide, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nirmal S. Basi whose telephone number is 571-272-0868. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda G Brumback can be reached on 571-272-0961. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Nirmal S. Basi
Art Unit 1646
September 27, 2004


BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

01/16

BIOTECHNOLOGY
SYSTEMS
BRANCH



1600

CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

TECH CENTER 1600/2900

Application Serial Number: 09/915,735
Filing Date: 7/26/2001
Date Processed by STIC: 4/2/2003

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

- The CRF (was): melted
- ☒ (circle one) Damaged or Unreadable (for Unreadable, see attached)
☐ Blank (no files on CRF) (see attached)
☐ Empty file (filename present, but no bytes in file) (see attached)
☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
☐ Not saved in ASCII text
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing.
☐ Did not contain a Sequence Listing. (see attached sample)
☐ Other: _____

PLEASE USE THE CHECKER VERSION 4.0 PROGRAM TO REDUCE ERRORS.
SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.


Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/efc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
EFFECTIVE MAY 1, 2003 (via USPS): Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/01/2003

BEST AVAILABLE COPY



Application No.:

09/ 915 735

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE